Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| PHOE | Phoenix Asia | $18.95 | -$114.17 | -85.77% | 129.7K | $2.9B | $2.31$133.12 |
| AREB | American Rebel | $2.18 | -$3.37 | -60.69% | 20.8K | $44M | $2.04$13,400.00 |
| BTOG | Bit Origin | $3.02 | -$1.02 | -25.25% | 176.1K | $9.1M | $2.58$60.60 |
| ATOS | Atossa Therapeutics | $6.34 | -$2.14 | -25.19% | 297.2K | $1.1B | $6.16$19.35 |
| ANL | Adlai Nortye | $8.16 | -$2.47 | -23.24% | 418.6K | $332M | $0.88$11.05 |
| BUUU | Buuu Group | $8.86 | -$2.63 | -22.89% | 29K | $192M | $3.67$20.76 |
| DFLI | Dragonfly Energy | $2.49 | -$0.71 | -22.19% | 943.6K | $39M | $1.50$26.10 |
| SOLT | Volatility Shares Trust - 2x Solana ETF | $4.29 | -$1.12 | -20.70% | 8.2M | - | $4.14$35.30 |
| IOTR | iOThree | $3.50 | -$0.91 | -20.64% | 61.4K | $11M | $2.24$59.80 |
| YEXT | Yext | $5.75 | -$1.42 | -19.76% | 1.8M | $878M | $5.51$9.20 |
| XPEG | Themes ETF Trust - Leverage Shares 2x Long Xpev Daily ETF | $9.20 | -$2.11 | -18.63% | 18.4K | - | $9.06$15.89 |
| WHLR | Wheeler Real Estate Investment Trust | $3.88 | -$0.88 | -18.49% | 74.7K | $3.3M | $3.76$6,793.50 |
| TXXS | Listed Funds Trust - 21Shares 2x Long Sui ETF | $9.27 | -$2.08 | -18.31% | 26.4K | - | $9.00$30.70 |
| VTIX | Virtuix | $5.62 | -$1.10 | -16.37% | 326.3K | $207M | $5.26$92.74 |
| PHAR | Pharming Group | $17.18 | -$3.29 | -16.07% | 77.5K | $1.4B | $7.50$21.34 |
| VIVS | VivoSim Labs | $2.46 | -$0.46 | -15.75% | 987.7K | $7.6M | $1.41$21.96 |
| HODU | Direxion Shares ETF Trust - Direxion Daily Hood Bull 2x ETF | $14.42 | -$2.53 | -14.92% | 40.5K | - | $13.70$35.58 |
| HOOG | Themes ETF Trust - Leverage Shares 2x Long Hood Daily ETF | $34.59 | -$6.01 | -14.80% | 257.6K | - | $6.88$132.19 |
| HOOX | Tidal Trust II - Defiance Daily Target 2x Long Hood ETF | $13.14 | -$2.27 | -14.73% | 205.3K | - | $2.26$45.53 |
Related Articles
Featured Article
Can Atossa Therapeutics Stock Keep Climbing?
Cory Renauer|Jun 28, 2021
Investors want to know if this clinical-stage cancer drug developer can keep putting up big gains.
2 Stocks I Bought Last Week, and 1 Stock I Sold
Rick Munarriz|Nov 11, 2020
This Fool bought into a fast-growing sports-first streaming service and a disruptive mattress maker. He also sold a tech stock cashing in on the credibility gap of online search.
3 Technology Stocks I'd Buy Right Now
Jon Quast|Apr 29, 2020
Don't let current economic uncertainty keep you away from these companies with long-term potential.
My Top Growth Stock for 2020
Simon Erickson|Jan 5, 2020
After seven years of New Year's recommendations, my average pick is up 112%. See which growth-style investment I'm tapping next.
Why Zoom Video Communications, PagerDuty, and Yext Slumped Today
Dan Caplinger|Dec 6, 2019
Even on a strong day on Wall Street, poor earnings held some stocks back.
Where Will Organovo Holdings, Inc. Be in 5 Years?
Cory Renauer|Dec 3, 2017
Will Organovo unlock the perceived value buried deep in its organ-printing technology by 2022?
Why Tiny Organovo Is Giving Money to Huge Biotech Amgen
Keith Speights|Aug 30, 2017
Organovo is paying Amgen researchers for their ideas on studying 3D bioprinted tissues. It could be money well spent.
Organovo Holdings Revenue Is Growing at a Snail's Pace Compared With Prior Quarters
Keith Speights|Aug 10, 2017
The 3D bioprinting company beat analyst revenue estimates in its fiscal first quarter -- but its losses worsened because of higher spending.
How Risky Is Organovo Holdings, Inc.?
Keith Speights|Jul 18, 2017
Organovo might be less risky than it's been in the past, but this stock still isn't for the faint of heart.
3 Reasons Organovo Holdings, Inc. Stock Could Fall Even More
Keith Speights|Jun 22, 2017
Could the beaten-down 3D bioprinting stock face even worse days ahead?
